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Articles

Incidence of typhoid and paratyphoid fever in Bangladesh,
Nepal, and Pakistan: results of the Surveillance for Enteric
Fever in Asia Project
Denise O Garrett, Ashley T Longley, Kristen Aiemjoy, Mohammad T Yousafzai, Caitlin Hemlock, Alexander T Yu, Krista Vaidya, Dipesh Tamrakar,
Shampa Saha, Isaac I Bogoch, Kashmira Date, Senjuti Saha, Mohammad Shahidul Islam, K M Ishtiaque Sayeed, Caryn Bern, Sadia Shakoor,
Irum F Dehraj, Junaid Mehmood, Mohammad S I Sajib, Maksuda Islam, Rozina S Thobani, Aneeta Hotwani, Najeeb Rahman, Seema Irfan,
Shiva R Naga, Ashraf M Memon, Sailesh Pradhan, Khalid Iqbal, Rajeev Shrestha, Hafizur Rahman, Md Mahmudul Hasan, Saqib H Qazi,
Abdul M Kazi, Nasir S Saddal, Raza Jamal, Mohammed J Hunzai, Tanvir Hossain, Florian Marks, Alice S Carter, Jessica C Seidman, Farah N Qamar*,
Samir K Saha*, Jason R Andrews*, Stephen P Luby*

Summary

Background Precise enteric fever disease burden data are needed to inform prevention and control measures,
including the use of newly available typhoid vaccines. We established the Surveillance for Enteric Fever in Asia Project
(SEAP) to inform these strategies.

Lancet Glob Health 2022;
10: e978–88
See Comment page e932
*Contributed equally

Methods From September, 2016, to September, 2019, we conducted prospective clinical surveillance for Salmonella
enterica serotype Typhi (S Typhi) and Paratyphi (S Paratyphi) A, B, and C at health facilities in predetermined
catchment areas in Dhaka, Bangladesh; Kathmandu and Kavrepalanchok, Nepal; and Karachi, Pakistan. Patients
eligible for inclusion were outpatients with 3 or more consecutive days of fever in the last 7 days; inpatients with
suspected or confirmed enteric fever; patients with blood culture-confirmed enteric fever from the hospital laboratories
not captured by inpatient or outpatient enrolment and cases from the laboratory network; and patients with nontraumatic ileal perforation under surgical care. We used a hybrid surveillance model, pairing facility-based blood
culture surveillance with community surveys of health-care use. Blood cultures were performed for enrolled patients.
We calculated overall and age-specific typhoid and paratyphoid incidence estimates for each study site. Adjusted
estimates accounted for the sensitivity of blood culture, the proportion of eligible individuals who consented and
provided blood, the probability of care-seeking at a study facility, and the influence of wealth and education on careseeking. We additionally calculated incidence of hospitalisation due to typhoid and paratyphoid.
Findings A total of 34 747 patients were enrolled across 23 facilitates (six tertiary hospitals, surgical wards of two
additional hospitals, and 15 laboratory network sites) during the study period. Of the 34 303 blood cultures performed
on enrolled patients, 8705 (26%) were positive for typhoidal Salmonella. Adjusted incidence rates of enteric fever
considered patients in the six tertiary hospitals. Adjusted incidence of S Typhi, expressed per 100 000 person-years,
was 913 (95% CI 765–1095) in Dhaka. In Nepal, the adjusted typhoid incidence rates were 330 (230–480) in Kathmandu
and 268 (202–362) in Kavrepalanchok. In Pakistan, the adjusted incidence rates per hospital site were 176 (144–216)
and 103 (85–126). The adjusted incidence rates of paratyphoid (of which all included cases were due to S Paratyphi A)
were 128 (107–154) in Bangladesh, 46 (34–62) and 81 (56–118) in the Nepal sites, and 23 (19–29) and 1 (1–1) in the
Pakistan sites. Adjusted incidence of hospitalisation was high across sites, and overall, 2804 (32%) of 8705 patients
with blood culture-confirmed enteric fever were hospitalised.
Interpretation Across diverse communities in three south Asian countries, adjusted incidence exceeded the threshold
for “high burden” of enteric fever (100 per 100 000 person-years). Incidence was highest among children, although
age patterns differed across sites. The substantial disease burden identified highlights the need for control measures,
including improvements to water and sanitation infrastructure and the implementation of typhoid vaccines.
Funding Bill & Melinda Gates Foundation.
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0
license.

Introduction
Enteric fever, due to Salmonella enterica serotype Typhi
(S Typhi) and Paratyphi (S Paratyphi) A, B, and C, is a
preventable disease causing an estimated 14 million
illnesses and 136 000 deaths worldwide in 2017.1 Illness
www.thelancet.com/lancetgh Vol 10 July 2022

is caused by ingesting faecally contaminated food
or water. Although enteric fever is largely controlled
in high-income countries through sanitation infra
structure improvements, in low-income and middleincome countries the disease is largely managed with
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Research in context
Evidence before this study
We searched PubMed, medRxiv, and SSRN for articles available
as of Feb 23, 2022, with no date or language restrictions, using
the search terms “(typhoid OR Salmonella Typhi OR Salmonella
Paratyphi OR enteric fever) AND (Bangladesh OR Nepal OR
Pakistan) AND (blood culture) AND (incidence)”. Typhoid fever
incidence from previous cohort studies and control groups of
vaccine trials was 210–452 per 100 000 person-years in
Karachi, Pakistan, 428–1062 per 100 000 in Lalitpur, Nepal,
and 635–1135 in Dhaka, Bangladesh, with variation over time
and by estimation method. Where reported, Salmonella
Paratyphi A incidence was substantially lower. Most studies
estimated incidence to be highest among children younger
than 10 years.
Added value of this study
Using a hybrid surveillance approach combining both active
clinical surveillance with health-care utilisation surveys, we
report new, robust estimates of enteric fever incidence from
population-based surveillance in Karachi, Pakistan; Kathmandu
and Kavrepalanchok, Nepal; and Dhaka, Bangladesh. Adjusted
incidences of typhoid per 100 000 person-years were 913
(95% CI 765–1095) in Dhaka, Bangladesh; 330 (230–480) in
Kathmandu, Nepal; 268 (202–362) in Kavrepalanchok, Nepal;

antibiotics.2,3 The spread of antimicrobial resistance is
undermining this management approach, however, as
increasing drug resistance makes enteric fever more
difficult and expensive to treat.4,5
In 2018, WHO recommended the use of the first
typhoid conjugate vaccine (TCV) for children as young
as 6 months in typhoid-endemic areas.6 Policy makers
in typhoid-affected countries must now decide whether,
and how, to introduce TCV into routine immunisation
schedules, including the optimal age, target population,
and delivery strategies. To make these decisions, timely
and accurate information on enteric fever disease
burden is required, including incidence and disease
outcome data and local geographical and demographic
distribution of typhoid.7–10
Previous typhoid burden estimates were generated using
active facility-based or passive augmented householdbased studies.11,12 Recent blood culture sentinel surveillance
studies are generating important data on the burden of
disease in select countries in Asia and sub-Saharan Africa.13
Yet for many countries in south Asia, there is limited
understanding of the true burden of enteric fever. The
Surveillance for Enteric Fever in Asia Project (SEAP), an
ongoing blood culture surveillance study, was initiated
in 2016 to describe the incidence, severity, and cost of
enteric fever in sites in Bangladesh, Nepal, and Pakistan.
SEAP was a two-phase study, with a retrospective
component (phase 1) from sites in India, Bangladesh,
Nepal, and Pakistan,14,15 and 3 years of prospective

and 103 (85–126) and 176 (144–216) in the two surveillance
sites for Karachi, Pakistan. The highest incidence was among
children aged 2–4 years in both Bangladesh and Pakistan, and
among individuals aged 5–25 years in Nepal. The adjusted
incidence of hospitalisation of typhoid cases ranged from
249 (69–1191) per 100 000 person-years in Kathmandu, Nepal
to 38 (28–57) per 100 000 person-years at Aga Khan University
Hospital in Karachi, Pakistan. Salmonella Paratyphi A incidence
per 100 000 person-years ranged from 1 (1–1) in one catchment
area in Karachi to 81 (56–118) in Kathmandu and
128 (107–154) in Dhaka. These estimates represent the first
population-based estimates for severe enteric fever,
highlighting a substantial burden of hospitalisation for enteric
fever in these communities. Our findings also document a high
incidence of typhoid across all ages of children.
Implications of all the available evidence
The high incidence of typhoid and notable rates of
hospitalisation in these study sites provides evidence needed to
support the introduction of the typhoid conjugate vaccine in
these settings, and the substantial burden among older
children and young adults highlights the need for catch-up
campaigns in addition to immunisation of young children.

surveillance (phase 2) in Bangladesh, Nepal, and Pakistan.
SEAP phase 2 findings on cost of illness, antimicrobial
resistance, patterns of health-care utilisation, severity of
illness, blood culture use, and clinical, behavioural, and
demographic factors of enteric fever were published
in 2020.16 Findings from the prospective surveillance in
India, the Surveillance for Enteric Fever in India project,
will be published elsewhere. Here, we present the enteric
fever incidence estimates from SEAP phase 2, with the
aim of informing policy makers in disease prevention and
control strategies.

Methods

Study design and participants
SEAP used a hybrid surveillance model, pairing
facility-based surveillance with community health-care
utilisation surveys to generate population-based enteric
fever incidence estimates.17
We conducted prospective clinical surveillance from
September, 2016, to September, 2019, at six tertiary
hospitals: Dhaka Shishu Hospital and Shishu Shasthya
Foundation Hospital in Dhaka, Bangladesh; Kathmandu
Medical College and Teaching Hospital (KMC) in
Kathmandu, and Dhulikhel Hospital, Kathmandu
University Hospital (DH-KUH) in Kavrepalanchok
District, Nepal; and Aga Khan University Hospital
(AKUH), and Kharadar General Hospital (KGH) in
Karachi, Pakistan. We also conducted surveillance within
the surgical wards of Jinnah Postgraduate Medical Centre
www.thelancet.com/lancetgh Vol 10 July 2022
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(JPMC) and the National Institute for Child Health
(NICH) in Karachi. Hospital sites in Bangladesh were
paediatric facilities serving patients aged 15 years or
younger, whereas sites in Nepal and Pakistan served both
children and adults. We also enrolled patients with blood
culture-positive enteric fever from 15 laboratory network
sites in all three countries (appendix p 2) to expand our
recruitment reach to patients seeking care outside the
participating study hospitals. The laboratory network
sites were hospitals and clinics with laboratory capacity
within the defined catchment areas that served both
adult and paediatric inpatients and outpatients. Patients
were therefore enrolled from a total of 23 health facilities.
Study site selection (of the six tertiary hospitals) is
described elsewhere.16,17
Using address information from patients with blood
culture-confirmed enteric fever identified from SEAP
phase 1, we defined catchment areas around each study
site hospital whereby more than 60% of the facility’s cases
were included.18 We then used census data or, in locations
where a census was not available, a geographically based
random sample to estimate the catchment area population
size and the age distribution; the latter enabled us to
capture changes due to migration during the study period.
All SEAP study site hospitals had a distinct catchment
area, except for the two site hospitals in Bangladesh,
which shared a catchment area. The catchment
populations included an urban and periurban area of
approximately 3·4 million people in Dhaka, Bangladesh;
an urban, periurban, and rural catchment area of
approximately 33 000 people in Kathmandu and
Kavrepalanchok district, Nepal; and an urban and
periurban area of approximately 3 million people,
including slum settlements, in Karachi, Pakistan.
Study participants were individuals of all ages with
febrile illness. Enrolment was offered to (1) outpatients
(including emergency department patients) residing
within the defined catchment area with 3 or more
consecutive days of fever in the last 7 days; (2) inpatients
with suspected or confirmed enteric fever; (3) patients
with blood culture-confirmed enteric fever from the
hospital laboratories not captured by inpatient or
outpatient enrolment and cases from the laboratory
network; and (4) surgical patients with non-traumatic
ileal perforation regardless of microbial confirmation. At
enrolment, interviewers asked questions on symptoms,
medication history, and care sought for the current
illness. Interviewers also asked questions on head of
household education and household assets to every other
patient enrolled in outpatient and inpatient wards, and to
all patients with blood culture-confirmed enteric fever. All
patients with blood culture-confirmed enteric fever were
contacted by telephone 6 weeks following enrolment to
ascertain self-reported hospitalisation after the enrolment
visit.
We obtained written informed consent from all
participants and the parents or guardians of participants
www.thelancet.com/lancetgh Vol 10 July 2022

younger than 18 years before blood collection and
completion of the questionnaire. We obtained written
assent from children aged 11–15 years in Bangladesh and
from children aged 15–17 years in Nepal and Pakistan.
Ethics review boards in the USA (Centers for Disease
Control and Prevention and Stanford University
Institutional Review Board), Bangladesh (Bangladesh
Institute of Child Health Ethical Review Committee),
Nepal (Nepal Health Research Council and Institutional
Review Committee, DH-KUH, and KMC), and Pakistan
(AKUH Ethics Review Committee and Pakistan National
Bioethics Committee) approved the study forms and
protocols.

See Online for appendix

Laboratory methods and data collection
Whole blood was collected before treatment and
incubated for up to 5 days using the BACTEC automated
culture system (Becton Dickinson, Franklin Lakes, NJ,
USA), or the BacTAlert 3D automated blood culture
system (BioMérieux, Marcy-l’Étoile, France). Positive
samples were subcultured onto MacConkey agar,
chocolate agar, or sheep blood agar (or a combination of
these), and species were confirmed using biochemical
testing and O and H antisera (MAST ASSURE, Mast
Group, Liverpool, UK), if available.19 Isolates obtained
from laboratory network sites were confirmed at the
study hospital laboratories using the same methods. All
hospital laboratories were enrolled in WHO or College of
American Pathologists external quality assurance
programmes.
To estimate the proportion of individuals with a febrile
illness in the catchment area compatible with enteric
fever who sought care at the study facilities, interviewers
administered a standard questionnaire to all households
within randomly selected clusters of the defined
catchment areas. The design and implementation of the
health-care utilisation survey, including sample size
calculations, are described elsewhere.20,21
We defined disease severity by hospitalisation.
Hospitalisation at the enrolment visit was documented
in the medical charts, and hospitalisation during the
6-week follow-up period was patient-reported.

Statistical analysis
We generated overall and age-specific typhoid and
paratyphoid incidence estimates for each study site. As
the Bangladesh sites shared a catchment area, the
incidence rates are presented together. The total number
of blood culture-confirmed cases was annualised
according to the recruitment period for each facility. The
annualised cases were then divided by the catchment
area population size to calculate the incidence rate.
We calculated crude incidence rates among patients
from within the hospital catchment areas with a positive
blood culture enrolled from outpatient, inpatient, and
surgical wards, as well as from hospital laboratories and
laboratory networks. In Nepal and Pakistan, patients of
e980

Articles

41 244 participants met study inclusion criteria
23 538 Bangladesh
7471 Nepal
10 235 Pakistan

6497 refused consent
6097 Bangladesh
256 Nepal
144 Pakistan

34 747 consented and enrolled
17 441 Bangladesh
7215 Nepal
10 091 Pakistan

444 blood not collected
14 Bangladesh
248 Nepal
182 Pakistan

34 303 blood collected
17 427 Bangladesh
6967 Nepal
9909 Pakistan

25 598 blood culture negative
12 554 Bangladesh
5365 Nepal
7679 Pakistan

8705 blood culture positive (7591 S Typhi, 1114 S Paratyphi A*)
4873 Bangladesh (4131 S Typhi, 742 S Paratyphi A)
1602 Nepal (1367 S Typhi, 235 S Paratyphi A)
2230 Pakistan (2093 S Typhi, 137 S Paratyphi A)

2635 residing outside catchment area
458 Bangladesh
1009 Nepal
1168 Pakistan

Figure 1: Recruitment,
eligibility, study consent,
and laboratory culture
positivity
*Two detected cases of S
Paratyphi B were excluded.
†Population for the crude
incidence rates includes ageeligible patients from within
the catchment area recruited
from outpatient departments,
inpatient departments,
surgical wards, hospital
laboratories, and laboratory
network sites. ‡Population for
the adjusted incidence rates
includes age-eligible patients
from within the catchment
area recruited from outpatient
departments, inpatient
departments, and surgical
wards.

e981

6070 residing within catchment area
4415 Bangladesh
593 Nepal
1062 Pakistan

940 aged >15 years
940 Bangladesh

5130 included in crude incidence rates† (4481 S Typhi, 649 S Paratyphi A)
3475 Bangladesh (3014 S Typhi, 461 S Paratyphi A)
593 Nepal (496 S Typhi, 97 S Paratyphi A)
1062 Pakistan (971 S Typhi, 91 S Paratyphi A)

1895 hospital laboratory and laboratory network patients (1617 S Typhi,
278 S Paratyphi)
1379 Bangladesh (1164 S Typhi, 215 S Paratyphi A)
317 Nepal (271 S Typhi, 46 S Paratyphi A)
199 Pakistan (182 S Typhi, 17 S Paratyphi A)

3235 included in adjusted incidence rates‡ (2864 S Typhi,
371 S Paratyphi A)
2096 Bangladesh (1850 S Typhi, 246 S Paratyphi A)
276 Nepal (225 S Typhi, 51 S Paratyphi A)
863 Pakistan (789 S Typhi, 74 S Paratyphi A)

any age were included. In Bangladesh, only children aged
15 years or younger were included in the calculations, as
the study site hospitals were paediatric facilities.
We calculated adjusted incidence among patients with
blood culture-confirmed enteric fever from within the
catchment areas enrolled from the outpatient, inpatient,
and surgical wards only. Patients recruited from
laboratories were excluded from the adjusted incidence
estimates (appendix pp 3–4) as participants with febrile
illness were not systematically enrolled and offered blood
cultures at those sites, precluding adjustment for
participation. The unadjusted incidence, different from
the crude incidence, describes the rate of age-eligible
case patients recruited from outpatient, inpatient, and
surgical wards before adjustments were applied.
The adjusted incidence estimates included adjustments
for (1) the sensitivity of blood culture (59%);22 (2) the
proportion of eligible individuals who consented and
provided blood; (3) the probability of seeking care at a
study site facility for individuals with suspected enteric
fever (data from the health-care utilisation survey); and
(4) the influence of wealth and education on care-seeking
at a study site (differential care-seeking). For further
details on adjustments see the appendix (pp 1, 3–4).
The incidence of hospitalisation was calculated
among outpatients, inpatients, and surgical ward
patients who were hospitalised at the enrolment visit or
were reportedly hospitalised in the 6 weeks after
enrolment. The adjustments included (1) the sensitivity
of blood culture; (2) the proportion of patients admitted
to hospital who consented and provided blood; (3) the
probability of being hospitalised for fever (data from
the health-care utilisation survey); and (4) the influence
of wealth and education on being hospitalised
(differential care-seeking for hospitalisation).
For each adjustment, we used a Monte Carlo approach
to create distributions for each adjustment probability
based on 1 million simulations and derived the median,
2·5th, and 97·5th percentiles. Age-specific adjustment
factors for the adjusted incidence calculations are
detailed in the appendix (pp 5–7).
All analyses were performed in R (version 4.1.2).

Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report.

Results
Across all surveillance sites, 41 244 individuals met the
study inclusion criteria during the study period,
34 747 (84%) of whom consented and were enrolled:
17 441 (74%) of 23 538 in Bangladesh, 7215 (97%) of 7471 in
Nepal, and 10 091 (99%) of 10 235 in Pakistan (figure 1).
Blood cultures were performed for 34 303 (99%) of
34 737 enrolled patients, with 8705 (26%) positive for
enteric fever (4873 [28%] of 17 427 in Bangladesh,
www.thelancet.com/lancetgh Vol 10 July 2022
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1602 [23%] of 6967 in Nepal, and 2230 [23%] of 9909 in
Pakistan). Most typhoidal Salmonella isolates across
countries were S Typhi: 4131 (85%) of 4873 in Bangladesh,
1367 (85%) of 1602 in Nepal, and 2093 (94%) of 2230 in
Pakistan (figure 1). Of a total of 1116 S Paratyphi isolates,
1114 (>99%) were Paratyphi A. Two cases of Paratyphi B
were detected (0·2%) and were excluded from the
analyses. No cases of Paratyphi C were detected.
19 868 (57%) of the enrolled participants were male and
14 879 (43%) were female. Most were recruited from
outpatient facilities (20 899 [60%]), whereas 248 (1%)
entered the study through surgical wards. The median
age of participants was 6 years (IQR 2–17), and
participants from Nepal were generally older than those
from Bangladesh and Pakistan (table 1). Although the
tertiary hospitals in Bangladesh were paediatric facilities,
1215 patients older than 15 years were enrolled from
laboratory network sites.
Among all patients with laboratory-confirmed typhoid,
the median age was 7 years (IQR 3–18), while the median
age of patients with laboratory-confirmed paratyphoid
was 12 years (5–23). Overall, 2804 (32%) patients with
laboratory-confirmed enteric fever were hospitalised at
the enrolment visit, with the highest percentage in
Pakistan (Bangladesh 27%, Nepal 28%, and Pakistan 47%;
table 1). Across countries, the majority of hospitalised
patients were male (male 1589 [57%], female 1215 [43%]),
and the median age was 7 years (3–16; table 1).
Among the 34 747 patients enrolled, 33 488 (96%)
resided within the catchment areas and met the age
criteria and were included in the crude incidence
analysis; 31 593 (91%) were recruited from outpatient,
inpatient, and surgical wards and were included in the
adjusted incidence analysis. None of the patients who
were blood culture-positive from JPMC and NICH
resided within the catchment areas. Overall, 2864 typhoid
cases and 371 paratyphoid cases were included in the
incidence rate calculations.
The crude incidence rates of enteric fever, expressed as
cases per 100 000 person-years, varied by and within
countries. The crude incidence rates of typhoid ranged
from 103 (95% CI 97–109) per 100 000 person-years in
Bangladesh to 12 (10–14) per 100 000 person-years at
AKUH in Pakistan (table 2). In Bangladesh, the crude
typhoid incidence was highest among children aged
2–4 years (217 [195–239] per 100 000 person-years),
whereas in both sites in Pakistan, the incidence was
highest among children younger than 2 years. In both
sites in Nepal, crude typhoid incidence peaked in patients
aged 16–25 years. The crude rates of paratyphoid were 16
(13–18) per 100 000 person-years in Bangladesh; 7 (3–16)
per 100 000 person-years at DH-KUH and 6 (4–9) per
100 000 person-years at KMC, in Nepal; and 3 (2–4)
per 100 000 person-years at AKUH and 0 (0–1) per
100 000 person-years at KGH, in Pakistan, following
similar age trends as the crude incidence of typhoid
(table 2).
www.thelancet.com/lancetgh Vol 10 July 2022

The ranking of the fully adjusted rates of typhoid by
site followed that of the crude incidence. The adjusted
typhoid incidence observed in Bangladesh was
913 (95% CI 765–1095) per 100 000 person-years. In
Nepal, the observed incidence at DH-KUH was
268 (202–362) per 100 000 person-years and at KMC was
330 (230–480) per 100 000 person-years; and in Pakistan,
it was 103 (85–126) per 100 000 person-years at AKUH
and 176 (144–216) per 100 000 person-years at KGH
(table 2, figure 2).
A high adjusted incidence of typhoid in children
younger than 2 years was observed in all study sites
(table 2, figure 3). The highest incidence was among
children aged 2–4 years in both Bangladesh and Pakistan,
and among individuals aged 5–25 years in Nepal.
Estimated incidence decreased with age in the older age
Bangladesh
(n=17 441)

Nepal
(n=7215)

Pakistan
(n=10 091)

Overall
(n=34 747)

Overall enrolment
Age, years

4 (2–7)

20 (8–31)

8 (3–22)

6 (2–17)
5759 (17%)

3751 (22%)

2–4 years

5708 (33%)

780 (11%)

1982 (20%)

8470 (24%)

5–15 years

6757 (39%)

1408 (20%)

2916 (29%)

11 081 (32%)

16–25 years

733 (4%)

2086 (29%)

1234 (12%)

4053 (12%)

>25 years

482 (3%)

2578 (36%)

2314 (23%)

5384 (15%)

16 071 (92%)

2655 (37%)

6440 (64%)

25 166 (72%)

Male

9912 (57%)

4204 (58%)

5752 (57%)

19 868 (57%)

Female

7529 (43%)

3007 (42%)

4339 (43%)

14 879 (43%)

10 991 (63%)

5047 (70%)

4861 (48%)

20 899 (60%)

3760 (22%)

866 (12%)

4209 (42%)

8835 (25%)

2 (<1%)

5 (<1%)

6 months–15 years

363 (5%)

1645 (16%)

<2 years

Sex

Study recruitment location
Outpatient department
Inpatient department
Surgical wards
Hospital laboratory
Laboratory network site

241 (2%)

248 (1%)

847 (5%)

229 (3%)

199 (2%)

1275 (4%)

1841 (11%)

1068 (15%)

581 (6%)

3490 (10%)

1602 (22%)

2230 (22%)

8705 (25%)

Laboratory-confirmed enteric fever cases
Total
Age, years
<2 years

4873 (28%)
6 (3–14)
449 (9%)

20 (15–25)
18 (1%)

6 (3–13)
305 (14%)

8 (4–19)
772 (9%)

2–4 years

1314 (27%)

46 (3%)

622 (28%)

1982 (23%)

5–15 years

1938 (40%)

313 (20%)

818 (37%)

3069 (35%)

16–25 years

688 (14%)

818 (51%)

288 (13%)

1794 (21%)

>25 years

484 (10%)

407 (25%)

197 (9%)

1088 (12%)

3733 (77%)

415 (26%)

479 (21%)

5899 (68%)

6 months–15 years
Sex
Male

2754 (57%)

942 (59%)

1286 (58%)

4982 (57%)

Female

2119 (43%)

660 (41%)

944 (42%)

3723 (43%)

1453 (30%)

266 (17%)

694 (31%)

2413 (28%)

732 (15%)

38 (2%)

748 (34%)

1518 (17%)

Study recruitment location
Outpatient department
Inpatient department
Surgical wards
Hospital laboratory
Laboratory network site

0 (0%)

1 (<1%)

8 (<1%)

9 (<1%)

847 (17%)

229 (14%)

199 (9%)

1275 (15%)

1841 (38%)

1068 (67%)

581 (26%)

3490 (40%)

(Table 1 continues on next page)
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Bangladesh
(n=17 441)

Nepal
(n=7215)

Pakistan
(n=10 091)

Overall
(n=34 747)

(Continued from previous page)
Hospitalised laboratory-confirmed enteric fever cases
Total

1295 (27%)

Age, years

5 (3–10)

<2 years

169 (13%)

2–4 years

419 (32%)

455 (28%)
19 (14–24)

1054 (47%)

7 (3–16)

7 (2%)

134 (13%)

310 (11%)

10 (2%)

288 (27%)

717 (26%)
995 (35%)

5–15 years

501 (39%)

103 (23%)

391 (37%)

16–25 years

126 (10%)

230 (51%)

145 (14%)

>25 years
6 months–15 years

80 (6%)

2804 (32%)

6 (3–13)

105 (23)

501 (18%)

96 (9%)

281 (10)

829 (79%)

2058 (73%)

1091 (84%)

138 (30%)

Male

733 (57%)

238 (52%)

618 (59%)

1589 (57%)

Female

562 (43%)

217 (48%

436 (41%)

1215 (43%)

Sex

Study recruitment location
Outpatient department

125 (10%)

53 (12%)

114 (11%)

292 (10%)

Inpatient department

732 (57%)

38 (8%)

748 (71%)

1518 (54%)

Surgical wards
Hospital laboratory
Laboratory network site

0 (0%)

1 (<1%)

8 (1%)

83 (6%)

58 (13%)

21 (2%)

162 (6%)

9 (<1%)

355 (27%)

305 (67%)

163 (15%)

823 (29%)

Data are median (IQR) or n (%). For the data beneath each row marked “Total”, the denominators for the percentages
are the numbers of patients listed in the respective “Total” rows.

Table 1: Demographic characteristics of patients enrolled (consented)

groups in Bangladesh and Pakistan, whereas it remained
high in individuals aged 5–25 years in Nepal (figure 3).
All incidence adjustments by age are detailed in the
appendix (pp 5–7).
Although lower than the rates of typhoid, the fully
adjusted incidence rates of paratyphoid followed the same
pattern, with the highest rates in Bangladesh and the
lowest in Pakistan (table 2, figure 2). In Bangladesh,
however, the highest incidence of paratyphoid was among
children aged 5–15 years (208 [95% CI 165–262] per
100 000 person-years; table 2, figure 3). At DH-KUH in
Nepal and AKUH in Pakistan, the highest incidence was
among participants aged 16–25 years (117 [65–233] per
100 000 person-years at DH-KUH and 60 [41–92] per
100 000 person-years at AKUH). At KMC in Nepal, the
highest adjusted incidence was among children aged
2–4 years (227 [103–521] per 100 000 person-years). There
were no observed cases of paratyphoid among participants
older than 4 years at KGH in Pakistan (figure 3).
The adjusted incidence of hospitalisation of patients
with typhoid ranged from 249 (95% CI 67–1191) per
100 000 person-years at KMC in Nepal to 38 (28–57) per
100 000 person-years at AKUH in Pakistan. Incidence of
hospitalisation was highest among children aged
2–4 years in Bangladesh; among individuals aged
5–15 years in DH-KUH and 16–25 years in KMC, in
Nepal; and among children younger than 2 years in both
sites in Pakistan. The highest incidence of hospitalisation
of patients with paratyphoid was among the same age
groups as those for typhoid in Bangladesh and KMC in
e983

Nepal. However, the adjusted incidence of hospitalisation
at DH-KUH in Nepal and AKUH in Pakistan was highest
among individuals aged 16–25 years. No patients with
paratyphoid were hospitalised at KGH in Pakistan
(table 2).

Discussion
We conducted prospective, population-based enteric
fever surveillance for 3 years to generate incidence data
on typhoid and paratyphoid in mostly urban and
periurban communities within Bangladesh, Nepal, and
Pakistan. Our incidence estimates—crude, unadjusted,
and adjusted rates—show a substantial burden of enteric
fever in all participating sites. Crude incidence rates are a
minimal estimate for enteric fever incidence and are
highly sensitive to the coverage of surveillance facilities,
which varied across catchment areas. Adjusted rates
varied by country, between different communities in a
country (eg, Kathmandu vs Kavrepalanchok, Nepal), and
by hospitals in the same city (eg, AKUH vs KGH in
Karachi, Pakistan). However, regardless of population
characteristics (eg, highly populated urban areas or lower
density periurban communities), all fully adjusted
incidence estimates exceeded the 100 per 100 000 personyears threshold used to define “high burden” settings for
enteric fever, with some surpassing the “very high”
incidence threshold (≥500 cases per 100 000 personyears).11,22,23 In addition to high overall incidence rates, we
observed a high adjusted incidence of severe disease
among case patients. The high rates of hospitalisation
indicate considerable morbidity and economic impact,
highlighting the need for control measures, including
the implementation of TCV.24–26
Our findings are consistent with previous studies
identifying typhoid in young children;27–29 our age-specific
incidence rates showed a high burden of disease in
children younger than 5 years, including those younger
than 2 years. These data emphasise the need to start TCV
immunisation as early as age 6 months, as recommended
by WHO.6 However, in Nepal, the adjusted incidence of
disease was higher among individuals 5 years and older,
highlighting the importance of understanding local
epidemiology for a tailored and more effective vaccination
strategy.
The hybrid surveillance approach used to estimate
incidence has several strengths. It allowed us to surveil a
large population and use systematically collected data to
adjust crude estimates to generate empirically based
incidence estimates.20 This hybrid framework captures a
full spectrum of disease, unlike cohort studies where
intensive, early testing and close follow-up might bias
towards milder cases. In our study, the large number of
confirmed cases improved the precision of our estimates
and permitted reliable, robust stratified analyses.
Additionally, we selected diverse surveillance sites and
investigated demographic determinants of care-seeking
through household surveys, adjusting for factors
www.thelancet.com/lancetgh Vol 10 July 2022
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Incidence of enteric fever
Salmonella Typhi
Crude incidence
per 100 000
person-years

Incidence of hospitalisation due to enteric fever
Salmonella Paratyphi A

Fully adjusted
incidence per
100 000 personyears

Crude incidence
per 100 000
person-years

Fully adjusted
incidence per
100 000 personyears

Salmonella Typhi
Crude incidence
per 100 000
person-years

Salmonella Paratyphi A
Fully adjusted
incidence per
100 000 personyears

Crude incidence
per 100 000
person-years

Fully adjusted
incidence per
100 000 personyears

Bangladesh: Dhaka Shishu Hospital and Shishu Shasthya Foundation Hospital
<2 years

160 (133–191)

780 (638–968)

22 (13–35)

81 (66–101)

59 (43–79)

374 (300–507)

4 (1–11)

38 (30–51)

2–4 years

217 (195–239)

1491 (1244–1804)

31 (23–41)

188 (157–228)

69 (57–82)

557 (448–755)

8 (4–13)

69 (56–94)

5–15 years
Overall

93 (86–101)

1302 (1038–1642)

15 (12–19)

208 (165–262)

24 (20–28)

200 (161–271)

3 (2–5)

30 (24–41)

103 (97–109)

913 (765–1095)

16 (13–18)

128 (107–154)

30 (27–33)

242 (195–328)

3 (2–5)

33 (26–44)

NA*

Nepal: Dhulikhel Hospital
<2 years

37 (1–311)

156 (100–259)

NA*

NA*

NA*

2–4 years

19 (1–164)

159 (102–262)

10 (0–109)

NA*

10 (0–109)

5–15 years

60 (28–116)

570 (310–1124)

9 (0–38)

114 (62–224)

31 (11–79)

123 (85–348)

2 (0–25)

16–25 years

67 (36–123)

406 (219–820)

17 (4–51)

117 (65–233)

13 (1–42)

103 (70–290)

2 (0–22)

>25 years

18 (9–36)

172 (119–256)

3 (0–12)

9 (6–14)

4 (1–15)

38 (26–106)

NA*

Overall

36 (24–51)

268 (202–362)

7 (3–16)

46 (34–62)

10 (5–20)

67 (46–189)

1 (0–7)

53 (36–151)

NA*

NA*

NA*

NA*
25 (17–70)
32 (22–92)
NA*
12 (8–34)

Nepal: Kathmandu Medical College
<2 years

8 (0–71)

251 (120–613)

9 (0–71)

NA*

8 (0–71)

178 (48–850)

NA*

NA*

2–4 years

28 (8–72)

227 (102–522)

9 (0–39)

227 (103–521)

12 (2–51)

140 (38–672)

NA*

NA*

5–15 years

46 (31–65)

423 (228–826)

7 (2–15)

66 (35–153)

16 (8–29)

398 (107–1890)

1 (0–8)

60 (16–287)

16–25 years

68 (53–84)

653 (313–1440)

12 (7–20)

169 (79–381)

19 (11–28)

504 (135–2394)

2 (0–6)

131 (35–624)

>25 years

11 (7–16)

130 (76–230)

3 (1–6)

34 (20–61)

2 (1–5)

96 (26–458)

1 (0–3)

25 (7–120)

Overall

31 (26–37)

330 (230–480)

6 (4–9)

81 (56–118)

9 (6–12)

249 (67–1191)

1 (0–3)

61 (16–291)

Pakistan: Aga Khan University Hospital
<2 years

43 (24–74)

282 (191–449)

1 (0–12)

10 (6–18)

20 (7–41)

138 (102–208)

1 (0–12)

4 (3–6)

2–4 years

36 (23–54)

371 (265–534)

4 (0–10)

38 (26–56)

19 (10–32)

116 (86–175)

1 (0–8)

9 (7–14)

5–15 years

25 (19–32)

280 (201–397)

3 (2–7)

42 (30–60)

11 (7–16)

71 (52–107)

1 (0–3)

9 (7–14)

16–25 years

11 (7–17)

152 (103–230)

4 (2–8)

60 (41–92)

5 (2–9)

36 (26–54)

1 (0–2)

14 (10–21)

3 (2–5)

22 (18–28)

2 (1–3)

10 (8–13)

1 (0–2)

10 (8–16)

0 (0–1)

4 (3–6)

12 (10–14)

103 (85–126)

3 (2–4)

23 (19–29)

6 (4–7)

38 (28–57)

1 (0–1)

8 (6–11)

>25 years
Overall

Pakistan: Kharadar General Hospital
<2 years

175 (122–244)

628 (470–889)

4 (0–28)

8 (6–12)

40 (17–79)

422 (307–708)

NA*

NA*

2–4 years

146 (113–185)

901 (662–1269)

1 (0–8)

6 (4–8)

36 (22–59)

394 (287–664)

NA*

NA*

5–15 years

29 (21–38)

344 (249–483)

16–25 years

3 (1–8)

>25 years
Overall

NA*

5 (2–10)

88 (64–147)

NA*

NA*

36 (24–57)

NA*

0 (0–2)

NA*

1 (0–4)

10 (8–18)

NA*

NA*

1 (0–3)

8 (6–10)

NA*

NA*

0 (0–2)

24 (21–28)

176 (144–216)

0 (0–1)

1 (1–1)

5 (3–7)

3 (2–5)
64 (46–107)

NA*

NA*

NA*

NA*

Crude incidence includes patients from within the catchment area recruited from outpatient departments, inpatient departments, surgical wards, hospital laboratories, and laboratory network sites. Fully
adjusted incidence includes patients from within the catchment area recruited from outpatient departments, inpatient departments, and surgical wards only. NA=not applicable. *No observed cases and
therefore insufficient data to estimate incidence.

Table 2: Crude and fully adjusted incidence rates of laboratory-confirmed Salmonella Typhi and Salmonella Paratyphi A and incidence of hospitalisation per 100 000 person-years, by age group

associated with care-seeking and typhoid risk in the
analyses to reduce bias in the estimates.30
There were limitations to this study. Although we
generated robust catchment-area-specific incidence
estimates, our estimates might not be generalisable to
other areas outside of our surveillance sites, or to similar
areas using different methods. A limitation to our
approach was the reliance on self-reporting for medical
history, hospitalisation after the enrolment visit, and
socioeconomic information. Although there is the
potential for recall bias in the medical history, the
www.thelancet.com/lancetgh Vol 10 July 2022

likelihood of imperfect recall is low for reported
hospitalisations in the 6 weeks following enrolment
given the short timeframe and no obvious incentive for
participants to either exaggerate or minimise their
symptoms. To mitigate misreporting of socioeconomic
information, we used questions related to head of
household education and household assets, which are
more reliable and less sensitive than household incomerelated questions. Our study locations were selected on
the basis of evidence of enteric fever18 and the capacity
for blood culture-based surveillance, which might result
e984
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Bangladesh: Dhaka Shishu Hospital
and Shishu Shasthya Foundation Hospital
Unadjusted

63 (59–68)

8 (7–10)

Adjustment 1

107 (99–117)

14 (13–16)

Adjustments 1 and 2

150 (138–163)

20 (19–22)

Adjustments 1, 2, and 3

963 (804–1160)

135 (113–163)

Adjustments 1, 2, 3, and 4 (fully adjusted)

913 (765–1095)

128 (107–154)

Nepal: Dulikhel Hospital
Unadjusted

24 (15–37)

4 (1–12)

Adjustment 1

40 (37–44)

7 (7–8)

Adjustments 1 and 2

42 (39–46)

8 (7–8)

Adjustments 1, 2, and 3

356 (291–437)

61 (50–75)

Adjustments 1, 2, 3, and 4 (fully adjusted)

268 (202–362)

46 (34–62)

Nepal: Kathmandu Medical College
Unadjusted

12 (9–16)

3 (2–5)

Adjustment 1

20 (19–22)

5 (5–6)
6 (5–6)

23 (21–25)

Adjustments 1 and 2
Adjustments 1, 2, and 3

359 (267–487)

87 (65–118)

Adjustments 1, 2, 3, and 4 (fully adjusted)

330 (230–480)

81 (56–118)

Pakistan: Aga Khan University Hospital
Unadjusted

10 (9–12)

2 (1–3)

Adjustment 1

18 (16–19)

4 (3–4)

Adjustments 1 and 2

18 (17–20)

4 (3–4)

Adjustments 1, 2, and 3

134 (110–163)

30 (25–37)

Adjustments 1, 2, 3, and 4 (fully adjusted)

103 (85–126)

23 (19–29)

Pakistan: Kharadar General Hospital
Unadjusted

21 (18–25)

0 (0–1)

Adjustment 1

36 (33–39)

0 (0–0)

Adjustments 1 and 2

36 (34–40)

0 (0–0)

Adjustments 1, 2, and 3

180 (154–210)

1 (1–1)

Adjustments 1, 2, 3, and 4 (fully adjusted)

176 (144–216)

1 (1–1)

0

25

100

500

1500

Salmonella Typhi incidence (cases per 100000 person-years)

0

25

100

Salmonella Paratyphi A incidence (cases per 100000 person-years)

Figure 2: Unadjusted and adjusted incidence rates of laboratory-confirmed typhoid and paratyphoid cases per 100 000 person-years, by adjustment factor and by study site
Adjustments are as follows: adjustment 1=culture sensitivity; adjustment 2=study consent; adjustment 3=care-seeking; adjustment 4=differential care-seeking. The points indicate the median
estimate and shaded areas indicate the density. The numbers to the right of each graph indicate the incidence estimate and the 95% confidence interval for each adjustment.

in higher incidence compared with rural, less densely
populated areas. More assessments in rural areas could
help inform the use of nationwide TCV roll-out versus
targeted vaccine campaigns. To further explore the
burden of disease in other areas, an ongoing
serosurveillance study was implemented in 2019 in the
SEAP sites and in rural areas of each country.
Serosurveillance could have the further advantage of
measuring the true force of infection in a population,
e985

including subclinical infections that are missed by
clinical surveillance. Similarly, we might have missed
cases of enteric fever at our study sites due to the
sensitivity of blood culture, which is even lower for
patients with previous antibiotic use.22 Data on previous
antibiotic use from within the SEAP sites are published
elsewhere.31 To address this limitation, we included the
estimated sensitivity of blood culture (59%) in our
incidence adjustments. Lastly, we annualised incidence
www.thelancet.com/lancetgh Vol 10 July 2022
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Bangladesh: Dhaka Shishu Hospital
and Shishu Shasthya Foundation Hospital
Age, years
>25
16–25
5–15

1302 (1038–1642)

208 (165–262)

2–4

1491 (1244–1804)

188 (157–228)

<2

780 (638–968)

81 (66–101)

172 (119–256)

9 (6–14)

16–25

406 (219–820)

117 (65–233)

5–15

570 (310–1124)

114 (62–224)

2–4

159 (102–262)

<2

156 (100–259)

Nepal: Dulikhel Hospital
Age, years
>25

Nepal: Kathmandu Medical College
Age, years
>25

34 (20–61)

130 (76–230)

16–25

653 (313–1440)

169 (79–381)

5–15

423 (228–826)

66 (35–153)

2–4

227 (102–522)

227 (103–521)

<2

251 (120–613)

Pakistan: Aga Khan University Hospital
Age, years
>25

22 (18–28)

10 (8–13)

16–25

152 (103–230)

60 (41–92)

5–15

280 (201–397)

42 (30–60)

2–4

371 (265–534)

38 (26–56)

<2

282 (191–449)

10 (6–18)

Pakistan: Kharadar General Hospital
Age, years
>25

8 (6–10)

16–25

36 (24–57)

5–15

344 (249–483)

2–4

901 (662–1269)

6 (4–8)

<2

628 (470–889)

8 (6–12)

0

25 100

500

1500

0

Salmonella Typhi incidence (cases per 100000 person-years)

25

100

Salmonella Paratyphi A incidence (cases per 100000 person-years)

Figure 3: Adjusted incidence estimates of typhoid and paratyphoid cases per 100 000 person-years, by age group and by study site
The points indicate the median estimate and shaded areas indicate the density. The numbers to the right of each graph indicate the incidence estimate and the 95% confidence interval for each age
group. There are no data plotted for Salmonella Typhi and Paratyphi A incidence among people aged 16–25 years and >25 years for the Bangladesh sites because these were paediatric facilities. There
are no data plotted for Salmonella Paratyphi A incidence among people aged <2 years and 2–4 years in Dulikhel Hospital (Nepal), aged <2 years in Kathmandu Medical College (Nepal), and aged 5–15
years, 16–25 years, and >25 years in Kharadar General Hospital (Pakistan), because there were no observed cases for these age groups and therefore insufficient data to estimate incidence.

rates and therefore did not capture seasonality of typhoid
transmission. However, we do not expect that seasonal
variability in transmission to influence TCV introduction
decisions.
The largest differences between the crude and adjusted
www.thelancet.com/lancetgh Vol 10 July 2022

incidence estimates were generated by the adjust
ment factor for health-care-seeking behaviours. This
adjustment rests on the assumption that individuals with
3 days or more of fever in the population have the same
rate of enteric fever infection as those who sought care.
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Although we showed that both care-seeking and blood
culture positivity varied by household education and
wealth status, when accounting for these variations, the
final adjusted estimates changed only marginally
compared with the estimates adjusted for health-careseeking alone. It is possible that there are residual
differences in health-care-seeking behaviour that we
could not measure, and for which we could not adjust.
Moreover, it is recognised that most patients with febrile
illness in south Asia do not have blood culture
performed,32 so a large adjustment in incidence for careseeking is expected.
Accurate, context-specific burden data on enteric fever,
such as those generated by SEAP, might inform TCV
introduction and the implementation of other enteric
fever prevention and control measures. Additionally,
population-based surveillance studies can serve as a
platform to measure the impact of vaccine introduction.
In the long term, surveillance can identify waning
protection and the need for revaccination, describe the
impact of vaccination on antimicrobial resistance, and
measure potential serotype replacement by S Paratyphi A.
In conclusion, the high burden of typhoid in the SEAP
study sites suggests that these communities would
benefit from TCV introduction. Early data from SEAP
contributed to the decision to introduce TCV in Pakistan,
where the Government launched the first nationwide
TCV introduction in 2019. In addition to data on typhoid
incidence, it is also important to monitor the burden
of paratyphoid as these data will also help inform
the introduction of upcoming bivalent S Typhi and
S Paratyphi A vaccines. Continued surveillance provides
insight into how factors such as increased urbanisation,
climate change, decreasing per capita water availability,
and rising drug resistance affect the epidemiology and
burden of enteric fever.
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